BIOX-101 demonstrates a powerful dual mode of action, targeting thromboinflammation at its source. It inhibits the activation of neutrophils – the human immune system’s first responders - and the release of neutrophil extracellular traps (NETs). It also inhibits Factors XIa and XIIa of the intrinsic coagulation pathway, exerting a powerful antithrombotic effect. Crucially, it does so without increasing bleeding.

In parallel, Bioxodes is developing a pipeline of drug candidates with the objectives to treat chronic thrombo-inflammatory and inflammatory diseases. The goal is to leverage the activity of BIOX-101 against neutrophil activation and NETs formation.